Veru FY26 Q2 net loss narrows to $2.74 million

Veru

Veru

VERU

0.00
  • Veru posted fiscal 2026 Q2 net loss of $2.7 million, or $0.12 per share, narrowing from $7.9 million, or $0.54 per share, a year earlier.
  • Operating loss improved to $7.2 million from $8.1 million, while R&D expense fell to $3.1 million from $3.9 million.
  • G&A expense dropped to $4.1 million from $5.2 million; cash, cash equivalents and restricted cash rose to $27.6 million at March 31 from $15.8 million at Sept. 30.
  • Phase 2b PLATEAU trial of enobosarm 3 mg with semaglutide in about 200 older patients with obesity was actively enrolling, with interim DXA data expected in Q1 2027 and final topline results expected in Q4 2027.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Veru Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202605130630PRIMZONEFULLFEED9718600) on May 13, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.